Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data.
暂无分享,去创建一个
D. Primorac | I. Mikula | Luka Boban | V. Molnar | Jasmina Catic | D. Erceg | L. Bach-Rojecky | Andrea Skelin | V. Matišić | L. Boban | Dalia Vađunec | Alen Juginović | Katarina Žunić | B. Arsov | I. Ivkošić | Lara Primorac | Bernard Esquivel | Morgan R. Donaldson | Jasmina Ćatić | I. E. Ivkošić | Vilim Molnar
[1] G. Mazandu,et al. Implementing Artificial Intelligence and Digital Health in Resource-Limited Settings? Top 10 Lessons We Learned in Congenital Heart Defects and Cardiology. , 2020, Omics : a journal of integrative biology.
[2] D. Primorac,et al. Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle. , 2019, Personalized medicine.
[3] Marcus Woo,et al. An AI boost for clinical trials , 2019, Nature.
[4] Tom Nadarzynski,et al. Acceptability of artificial intelligence (AI)-led chatbot services in healthcare: A mixed-methods study , 2019, Digital health.
[5] Jianying Hu,et al. Artificial intelligence and machine learning in clinical development: a translational perspective , 2019, npj Digital Medicine.
[6] E. Heard,et al. Advances in epigenetics link genetics to the environment and disease , 2019, Nature.
[7] Ravishankar K. Iyer,et al. Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication , 2019, Clinical pharmacology and therapeutics.
[8] Phedias Diamandis,et al. Physician perspectives on integration of artificial intelligence into diagnostic pathology , 2019, npj Digital Medicine.
[9] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy , 2019, Clinical pharmacology and therapeutics.
[10] A. Seyhan,et al. Are innovation and new technologies in precision medicine paving a new era in patients centric care? , 2019, Journal of Translational Medicine.
[11] D. Primorac,et al. Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. , 2019, Personalized medicine.
[12] K. Chung,et al. Implementing Precision Medicine and Artificial Intelligence in Plastic Surgery: Concepts and Future Prospects , 2019, Plastic and reconstructive surgery. Global open.
[13] Sephalie Y. Patel,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes , 2019, Clinical pharmacology and therapeutics.
[14] M. Relling,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update , 2019, Clinical pharmacology and therapeutics.
[15] Eric J Topol,et al. High-performance medicine: the convergence of human and artificial intelligence , 2019, Nature Medicine.
[16] Andre Esteva,et al. A guide to deep learning in healthcare , 2019, Nature Medicine.
[17] Jie Xu,et al. The practical implementation of artificial intelligence technologies in medicine , 2019, Nature Medicine.
[18] P. Kasi,et al. Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma , 2018, Front. Pharmacol..
[19] F. Sardanelli,et al. Artificial intelligence in medical imaging: threat or opportunity? Radiologists again at the forefront of innovation in medicine , 2018, European Radiology Experimental.
[20] G. Hessler,et al. Artificial Intelligence in Drug Design , 2018, Molecules.
[21] Holger Fröhlich,et al. From hype to reality: data science enabling personalized medicine , 2018, BMC Medicine.
[22] Ahmed Hosny,et al. Artificial intelligence in radiology , 2018, Nature Reviews Cancer.
[23] D. Primorac,et al. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. , 2018, Personalized medicine.
[24] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy , 2018, Clinical pharmacology and therapeutics.
[25] Julie A. Johnson,et al. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine , 2018, Expert opinion on drug metabolism & toxicology.
[26] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update , 2018, Clinical pharmacology and therapeutics.
[27] Julia M. Barbarino,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update , 2018, Clinical pharmacology and therapeutics.
[28] S. Mohamad R. Soroushmehr,et al. Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification , 2018, Pharmacogenomics.
[29] A. Lukowiak,et al. Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings , 2018, Neuropsychiatric disease and treatment.
[30] T. Park,et al. Analysis of population-specific pharmacogenomic variants using next-generation sequencing data , 2017, Scientific Reports.
[31] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update , 2017, Clinical pharmacology and therapeutics.
[32] Rj H Gordon,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron , 2017, Clinical pharmacology and therapeutics.
[33] Julia M. Barbarino,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy , 2017, Clinical pharmacology and therapeutics.
[34] K. Sangkuhl,et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.
[35] R. Shah. Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy? , 2017, Therapeutic advances in drug safety.
[36] Kalpana Raja,et al. Machine learning workflow to enhance predictions of Adverse Drug Reactions (ADRs) through drug-gene interactions: application to drugs for cutaneous diseases , 2017, Scientific Reports.
[37] Sivanesan Dakshanamurthy,et al. Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools. , 2017, Current drug metabolism.
[38] Laura Shafner,et al. Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy , 2017, Stroke.
[39] Demis Hassabis,et al. Artificial Intelligence: Chess match of the century , 2017, Nature.
[40] W. Chung,et al. Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation , 2016, International journal of molecular sciences.
[41] F. Carvalho,et al. Comparative metabolism of tramadol and tapentadol: a toxicological perspective , 2016, Drug metabolism reviews.
[42] M. Weale,et al. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? , 2016, The Pharmacogenomics Journal.
[43] Muhammad Badruddin Khan,et al. Machine Learning: Algorithms and Applications , 2016 .
[44] M. Pirmohamed,et al. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions , 2016, PharmacoEconomics.
[45] S. Vegter,et al. Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature , 2016, PloS one.
[46] Y. Teo,et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics , 2015, Pharmacogenetics and genomics.
[47] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.
[48] Julia M. Barbarino,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing , 2015, Clinical pharmacology and therapeutics.
[49] Richard Ofori-Asenso,et al. Perspective: Does personalized medicine hold the future for medicine? , 2015, Journal of pharmacy & bioallied sciences.
[50] R. Shah,et al. Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine , 2015, Drug Metabolism and Disposition.
[51] R. Shah,et al. Addressing phenoconversion: the Achilles' heel of personalized medicine , 2015, British journal of clinical pharmacology.
[52] H. Ho,et al. Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations , 2015, British journal of clinical pharmacology.
[53] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing , 2014 .
[54] L Gong,et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.
[55] C. Altar,et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. , 2014, Psychiatric services.
[56] M. Relling,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype , 2014, Clinical pharmacology and therapeutics.
[57] E. McDonagh,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype , 2014, Clinical pharmacology and therapeutics.
[58] T. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.
[59] L. Gong,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens , 2014, Clinical pharmacology and therapy.
[60] Janet Sultana,et al. Clinical and economic burden of adverse drug reactions , 2013, Journal of pharmacology & pharmacotherapeutics.
[61] J. Mega,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[62] C. Rotimi,et al. Pharmacogenomics, ancestry and clinical decision making for global populations , 2013, The Pharmacogenomics Journal.
[63] Darcy A. Davis,et al. Bringing Big Data to Personalized Healthcare: A Patient-Centered Framework , 2013, Journal of General Internal Medicine.
[64] K. Tansey,et al. Contribution of Common Genetic Variants to Antidepressant Response , 2013, Biological Psychiatry.
[65] C. Thorn,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing , 2013, Clinical pharmacology and therapeutics.
[66] T. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing , 2012, Clinical pharmacology and therapeutics.
[67] F. Fonseca,et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. , 2012, International journal of cardiology.
[68] L. Hood,et al. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine , 2012, Journal of internal medicine.
[69] N. Clark,et al. Alleviating suffering 101--pain relief in the United States. , 2012, The New England journal of medicine.
[70] Christine W. Duarte,et al. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans , 2011, Bioinform..
[71] L. Hood,et al. Predictive, personalized, preventive, participatory (P4) cancer medicine , 2011, Nature Reviews Clinical Oncology.
[72] G. Novelli,et al. Personalized genomic medicine , 2010, Internal and emergency medicine.
[73] Subin Mary Zachariah,et al. Pharmacogenomics: The Right Drug to the Right Person , 2009, Journal of clinical medicine research.
[74] E. Antman,et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials , 2009, The Lancet.
[75] B. Schackman,et al. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer , 2009, Cancer.
[76] M Heath-Chiozzi,et al. Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.
[77] B K Tang,et al. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. , 1998, Pharmacogenetics.
[78] R. Herings,et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme , 1995, The Lancet.
[79] D Servan-Schreiber,et al. Artificial Intelligence and Psychiatry , 1986, The Journal of nervous and mental disease.
[80] A. M. Turing,et al. Computing Machinery and Intelligence , 1950, The Philosophy of Artificial Intelligence.
[81] Nicholas J Schork,et al. Artificial Intelligence and Personalized Medicine. , 2019, Cancer treatment and research.
[82] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing , 2016, Clinical pharmacology and therapeutics.
[83] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[84] Russ B Altman,et al. PharmGKB: the Pharmacogenomics Knowledge Base. , 2013, Methods in molecular biology.